[14C]ABT-199 (GDC-0199)
Phase 1Withdrawn 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Non-Hodgkin's Lymphoma
Conditions
Relapsed/Refractory Non-Hodgkin's Lymphoma
Trial Timeline
Sep 1, 2014 โ Jan 1, 2015
NCT ID
NCT02095574About [14C]ABT-199 (GDC-0199)
[14C]ABT-199 (GDC-0199) is a phase 1 stage product being developed by AbbVie for Relapsed/Refractory Non-Hodgkin's Lymphoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02095574. Target conditions include Relapsed/Refractory Non-Hodgkin's Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02095574 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Relapsed/Refractory Non-Hodgkin's Lymphoma